FDA Clears Atossa Therapeutics to Proceed with (Z)-Endoxifen Trial for Metastatic Breast Cancer

Reuters01-06

FDA Clears Atossa <a href="https://laohu8.com/S/LENZ">Therapeutics</a> to Proceed with <a href="https://laohu8.com/S/Z">$(Z)$</a>-Endoxifen Trial for Metastatic Breast Cancer

Atossa Therapeutics Inc. has received a "Study May Proceed" letter from the U.S. Food and Drug Administration (FDA) for its investigational new drug application of (Z)-endoxifen for metastatic breast cancer. This regulatory milestone allows Atossa to advance clinical studies of (Z)-endoxifen, a selective estrogen receptor modulator/degrader (SERM/D) with a distinct safety profile and pharmacology from tamoxifen. The company is evaluating the drug’s potential in treating metastatic ER+/HER2- breast cancer, including cases resistant to other endocrine therapies. Atossa’s (Z)-endoxifen is not yet approved for any indication.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atossa Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF56883) on January 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2601972758?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-06 21:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2601972758","market":"fut","top_or_hot":-1,"title":"FDA Clears Atossa Therapeutics to Proceed with (Z)-Endoxifen Trial for Metastatic Breast Cancer","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      FDA Clears Atossa <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> to Proceed with <a href=\"https://laohu8.com/S/Z\">$(Z)$</a>-Endoxifen Trial for Metastatic Breast Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Atossa Therapeutics Inc. has received a \"Study May Proceed\" letter from the U.S. Food and Drug Administration (FDA) for its investigational new drug application of (Z)-endoxifen for metastatic breast cancer. This regulatory milestone allows Atossa to advance clinical studies of (Z)-endoxifen, a selective estrogen receptor modulator/degrader (SERM/D) with a distinct safety profile and pharmacology from tamoxifen. The company is evaluating the drug’s potential in treating metastatic ER+/HER2- breast cancer, including cases resistant to other endocrine therapies. Atossa’s (Z)-endoxifen is not yet approved for any indication.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atossa Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF56883) on January 06, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA Clears Atossa Therapeutics to Proceed with (Z)-Endoxifen Trial for Metastatic Breast Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA Clears Atossa Therapeutics to Proceed with (Z)-Endoxifen Trial for Metastatic Breast Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-06 21:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      FDA Clears Atossa <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> to Proceed with <a href=\"https://laohu8.com/S/Z\">$(Z)$</a>-Endoxifen Trial for Metastatic Breast Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Atossa Therapeutics Inc. has received a \"Study May Proceed\" letter from the U.S. Food and Drug Administration (FDA) for its investigational new drug application of (Z)-endoxifen for metastatic breast cancer. This regulatory milestone allows Atossa to advance clinical studies of (Z)-endoxifen, a selective estrogen receptor modulator/degrader (SERM/D) with a distinct safety profile and pharmacology from tamoxifen. The company is evaluating the drug’s potential in treating metastatic ER+/HER2- breast cancer, including cases resistant to other endocrine therapies. Atossa’s (Z)-endoxifen is not yet approved for any indication.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atossa Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF56883) on January 06, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nNDL46cVHM:1","article_id":"2601972758","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2601972758","pubTimestamp":1767705329,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Atossa Therapeutics Inc. has received a \"Study May Proceed\" letter from the U.S. Food and Drug Administration  for its investigational new drug application of -endoxifen for metastatic breast cancer. This regulatory milestone allows Atossa to advance clinical studies of -endoxifen, a selective estrogen receptor modulator/degrader  with a distinct safety profile and pharmacology from tamoxifen. The company is evaluating the drug’s potential in treating metastatic ER+/HER2- breast cancer, including cases resistant to other endocrine therapies. Atossa’s -endoxifen is not yet approved for any indication.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atossa Therapeutics Inc. published the original content used to generate this news brief v","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ATOS":"Atossa Genetics Inc"},"translate_title":"FDA批准Atossa Therapeutics继续进行(Z)-内昔芬治疗转移性乳腺癌的试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ATOS":0.9},"content_text":"FDA Clears Atossa Therapeutics to Proceed with $(Z)$-Endoxifen Trial for Metastatic Breast Cancer\n    \n\n        Atossa Therapeutics Inc. has received a \"Study May Proceed\" letter from the U.S. Food and Drug Administration (FDA) for its investigational new drug application of (Z)-endoxifen for metastatic breast cancer. This regulatory milestone allows Atossa to advance clinical studies of (Z)-endoxifen, a selective estrogen receptor modulator/degrader (SERM/D) with a distinct safety profile and pharmacology from tamoxifen. The company is evaluating the drug’s potential in treating metastatic ER+/HER2- breast cancer, including cases resistant to other endocrine therapies. Atossa’s (Z)-endoxifen is not yet approved for any indication.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atossa Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF56883) on January 06, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2601972758","isCrawlerRequest":true}